Abstract
The objective of this work was to estimate the incidence rate of cardiovascular disease (CVD) events (myocardial infarction, stroke or CVD-death) at 1 year among 3 cohorts of patients at high risk of fracture (osteoporosis; previous fracture; and anti-osteoporosis medication), and to identify the key risk factors of CVD events in these three cohorts. To do so, this prospective cohort study used data from the Clinical Practice Research Datalink, a primary care database from United Kingdom. MACE events (a composite outcome for the occurrence of either myocardial infarction (MI), stroke or CVD death) were identified in patients aged fifty or over at high or imminent fracture risk identified in three different cohorts (not mutually exclusive): recently diagnosed with osteoporosis (OST, n=65,295), incident fragility fracture (IFX, n=80,587), and starting oral bisphosphonates (OBP, n=145,959). MACE incidence rates (cases/1000 person-years) were: 19.63 (18.54;20.73) in OST, 51.09 (49.39;52.80) in IFX, and 26.26 (25.41;27.12) in OBP cohorts. Candidate risk factors from QRISK tool, and candidates from literature selected by lasso regression, were fitted into prediction models to estimate 1-year risk of MACE for each cohort. OST and OBP models had a discrimination of ≥ 70% and IFX cohort ≥ 60%. Calibration plots showed good internal validity of the models. Generally, models from lasso regression were better than QRISK. Main risk factors common in all MACE models were sex, alcohol, atrial fibrillation, anti-hypertensive medication, age, prior MI/stroke, established CVD, glomerular filtration rate, systolic blood pressure, and number of GP visits and concomitant medicines. Incidence of MACE in the studied populations was 4.35% or lower, with IFX as the cohort with the higher risk. Identified key risk factors highlight the differences of patients at high risk of fracture versus general population. Proposed models could improve prediction of CVD events in patients with osteoporosis in primary care settings.
Competing Interest Statement
All authors have completed the ICMJE disclosure form at http://www.icmje.org/disclosure-of-interest/ and declare the following interests: MPM, LE, AD, CC, and SK have no conflict to declare. DPA reports institutional grant from NIHR, grants from Chesi-Taylor and Novartis, grants and other supports from Amgen and UCB Biopharma, and other supports from Astellas, AstraZeneca, Johnson and Johnson, Janssen - on behalf of IMI-funded EHDEN and EMIF consortiums -, and Synapse Management Partners. MA, CL, and ET are current employees of UCB Biopharma and hold stock shares of the company.
Funding Statement
The study was sponsored by Amgen and UCB Pharma. The study funders play a role in the conceptualisation, study design, and preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Independent Scientific Advisory Committee of the Clinical Practice Research Datalink gave ethical approval for this work with protocol number 18_116R.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Joint first authors
Data Availability
Data that supports the findings of this study was provided by UK CPRD database. Availability of data is subject to protocol approval by CPRD's Research Data Governance Process.
